Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Axsome Therapeutics, Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provided written informed consent to participate in Study AXS-05-301
Has treatment-resistant depression, defined as an inadequate response to 2 or 3 prior ADTs
Body mass index (BMI) between 18 and 40 kg/m2, inclusive
You may not be if
Suicide risk
Treatment with any investigational drug within 6 months
History of electroconvulsive therapy (ECT), vagus nerve stimulation, transcranial magnetic stimulation, or any experimental central nervous system treatment during the current episode or in the past 6 months
Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
Clareo Health | An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients
